More than 500 listed pharmaceutical and biotechnology companies have disclosed their first quarter reports, with nearly 80% achieving profits.

In the first quarter of 2026, the commercialization of domestically innovative drugs accelerated and overseas licensing transactions were intensively realized, driving the performance improvement of many listed pharmaceutical companies. According to incomplete statistics from reporters, as of April 30th, more than 500 pharmaceutical and biotech listed companies have disclosed their first quarter reports for 2026, with nearly 80% achieving profits. Reporters noted that the demand dividend for innovative drugs is transmitted along the industry chain, empowering the upstream and downstream tracks such as CXO and biomaterials, leading to a continuous increase in industry prosperity. At the same time, domestic pharmaceutical companies are continuously strengthening their innovative core through strategic transformation, increased research and development, and active international expansion. Several experts in the pharmaceutical industry told reporters that with multiple advantages in technology, cost, and industrialization, domestic innovative drugs have strong momentum in going global and the industry chain has strong resilience, which is expected to open up new space for the high-quality development of the industry.